TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations

1. Subjects

To validate the association between common variants in lysosomal genes from the reported GWA study of PD³, large-scale Neurobooster genotyping imputed data obtained from GP2 release 10 (https://gp2.org/the-components-of-gp2s-8th-data-release/) was analysed, which contains 33,813 cases and 18,714 controls in 11 ancestries: GP2-African American (GP2-AAC: 369 cases, 756 controls), GP2-African (GP2-AFR: 1,147 cases, 2,179 controls), GP2-Ashkenazi Jewish (GP2-AJ: 1,285 cases, 408 controls), GP2-Latino and indigenous Americas (GP2-AMR: 1,917 cases, 1,402 controls), GP2-Central Asian (GP2-CAS: 734 cases, 578 controls), GP2-East Asian (GP2-EAS: 2,377 cases, 2,598 controls), GP2-European (GP2-EUR: 24,208 cases, 9,662 controls), GP2-Finnish (GP2-FIN: 80 cases, 11 controls) population isolate; GP2-Middle Eastern (GP2-MDE: 724 cases, 551 controls), GP2-South Asian (GP2-SAS: 309 cases, 261 controls), GP2-Complex Admixture History (GP2-CAH: 663 cases, 318 controls). To minimize potential bias, individuals carrying GBA1 risk variants were excluded from all ancestries. Quality control analyses at a sample and variant level for this GP2 dataset are described elsewhere (https://github.com/GP2code/GenoTools)¹⁹. To validate the association between rare variants in GBA1 and PD risk, WGS data from AMP-PD release 4 (https://www.amp-pd.org/news/gp2-release-notes-november-2023) was analysed, which contains 3,188 cases and 4,104 controls from EUR ancestry. Information about the quality control steps performed on the AMP-PD dataset can be found at: https://amp-pd.org/whole-genome-data. Cases and controls with missing covariates (including gender and age) were removed.

2. Gene region extraction and variants annotation

Regions of each gene were extracted with PLINK 2.0 based on the gene locations according to the Ensembl genome browser (https://www.ensembl.org/Homo_sapiens/), including 50 kb downstream and upstream of the genes. Variants were annotated using ANNOVAR²⁰, and variants were defined as (1) exonic, (2) non-synonymous and loss of function (Nonsyn and LoF). LoF included stopgain, stoploss and frameshift variants.

3. Statistical analysis

Imputed genotype data often struggles to accurately capture rare variants (MAF <1%) in complex genomic regions such as GBA1 locus because of poor imputation quality and genomic complexity. Therefore, GP2 Neurobooster data was used to assess both common variants and rare variants in the genes TMEM175, SCARB2 and CTSB, while AMP-PD WGS data was used to conduct rare variant association analysis in the GBA1 gene.

Association analyses were performed with PLINK 2.0²¹, adjusted by gender, age and the first five genetic principal components (PCs) in each ancestry.

Conditional and joint (COJO) analysis was conducted to determine if there are independent signals per ancestry with genome-wide complex trait analysis (GCTA) software version 1.94.1^22,23. To identify gene-wide significant signals in the absence of genome-wide significance (p <5×10^⁻8), we established gene-specific significant thresholds through linkage disequilibrium (LD) pruning followed by Bonferroni correction. LD pruning was performed to define a p-value threshold for the COJO analysis in GP2 NeuroBooster array (parameters: --indep-pairwise 50 50 0.5). We identified 107 independent variants in TMEM175, 141 variants in SCARB2 and 116 variants in CTSB. Therefore, the thresholds for p values which were used in conditional analysis were: 4.67e-4 (0.05/107, TMEM175), 3.55e-4 (0.05/141, SCARB2), 4.31e-4 (0.05/116, CTSB). In addition, LDpair tool (https://ldlink.nih.gov/?tab=ldpair) was used to validate if these signals were independent of known GWAS hits. Regional plots were generated with the online tool LocusZoom.js (https://statgen.github.io/localzoom/)²⁴.

WGS data obtained from AMP-PD release 4.0 (https://www.amp-pd.org/news/gp2-release-notes-november-2023) and GP2 NeuroBooster array dataset was used separately to assess whether TMEM175, SCARB2, CTSB and GBA1 have an excessive genetic burden on PD. Gene-based burden tests were performed using RVTESTS²⁵ to assess the cumulative effects of rare variants on the risk for PD. Analyses were performed twice for each gene, once for all exonic variants and once for the stricter subset of Nonsyn+LoF variants. Benjamini–Hochberg procedure was used to adjust the raw P-values for multiple testing. Furthermore, single-variant-based tests were conducted with RVTESTS to find single statistically significant variants which have an impact on PD risk. All burden analyses were adjusted for age, gender and PC1-PC5.

All analyses were performed using R statistical language, Python and linux programming language on Terra (https://terra.bio/) and Verily workbench (https://workbench.verily.com/).

Our overall analytic approach is illustrated in Figure 1.

• Download figure
• Open in new tab

Figure 1. General overview of analysis

Abbreviations, maf, minor allele frequency; WGS, whole genome sequencing; Nonsyn and LoF, non-synonymous variants.

1. Association analysis of known common risk variants in TMEM175, SCARB2, and CTSB across 11 populations

2. Identification of independent signals with conditional analysis across 11 populations

3. Burden analysis with GP2 Neurobooster array and AMP-PD datasets

To test if an aggregate burden of rare variants in TMEM175, SCARB2 and CTSB contributes to the risk of PD, SKAT-O analysis was conducted within the GP2 Neurobooster array data across 11 populations (Table 3).

TMEM175

The rs34311866 missense variant p.M393T in the TMEM175 gene was the most strongly associated signal in the region. The association reached genome-wide significance and TMEM175 rs34311866 was identified as a single independent risk factor of PD in the European population, aligning with previous reports³. In addition, it was associated with PD in Ashkenazi Jewish, Latino and indigenous Americas, Middle Eastern and South Asian populations, which could be possibly due to a haplotype block including rs34311866 variant in these other populations. Another common variant rs34884217 p.Q65P, as a secondary signal in the same locus, was found to be associated with reduced PD risk in a previous study²⁷. In this study, the frequency of the protective allele was also significantly higher in the controls than in cases across Ashkenazi Jewish, European and Middle Eastern populations. Notably, due to the minor allele frequency (MAF) threshold of 0.01 for common variants, TMEM175 rs34311866 and rs34884217 in the African, and TMEM175 rs34884217 in the East Asian populations, were not included in the analysis in these populations.

We went further to identify independent signals in TMEM175 using GCTA-COJO analysis in other populations. Genotypes at rs6599388 in the TMEM175 gene was detected as an independent intronic variant for PD risk with GCTA-COJO in the Ashkenazi Jewish population. Of note, TMEM175 rs6599388 was correlated with rs34311866. It was also previously reported to be associated with PD in GWA studies in the European population (2011 PD GWAS, rs6599388, odds ratio [OR] = 1.16)²⁸. In the East Asian population, conditional analysis identified rs3755956 as a novel, independent association signal at the TMEM175 locus.

No statistically significant associations of rare variants in the TMEM175 gene were found for any ancestral populations. A previous study did not show significant results in 2,657 patients and 3,647 controls in a TMEM175 burden analysis²⁹. Our finding was consistent with this previous study, supported by sufficient statistical power, suggesting that a cumulative burden of rare variants in the TMEM175 gene does not contribute significantly to PD risk.

SCARB2

Regarding SCARB2, our findings support previous reports that genotypes at rs6812193 and rs6825004 in the SCARB2 gene were found associated with PD in the European ancestry^3,8,17,18. Interestingly, we observed a significant association between SCARB2 rs6812193 and PD in the Latino and indigenous Americas population, between SCARB2 rs6825004 and PD in the Middle Eastern and Complex Admixture History populations. Besides this, we also identified one novel independent non-coding common genetic variant(rs11547135) in the European population. In the Ashkenazi Jewish population, rs530111925 at the SCARB2 locus was identified as a novel, independent variant. Excessive genetic burden of SCARB2 rare variants was not replicated in the European population. Previous studies had shown a possible association between SCARB2 rare variants and PD risk with SKAT-O test^7,29. This may be attributed to genetic and demographic differences among populations from different regions or lack of statistical power. Interestingly, SCARB2 rare variants in exonic regions were found to be associated with PD risk in three other populations, the African American, the Ashkenazi Jewish, and the East Asian cohorts. Moreover, we found 5 novel single genetic variants (rs149997095, rs957776724, rs143518519, rs147159813 and rs35069772) significantly associated with increased PD risk in the African American population and none of which have previously been reported to be associated with PD in ClinVar. In the Ashkenazi Jewish cohort, single-variant-based tests showed that rs143655258 had a protective effect on PD. This variant results in an amino acid change, p. Met159Val, and has not been reported before in the context of PD risk. In the East Asian population, we identified two single significant missense variants, SCARB2 rs773017713 and rs117600063, resulting in the p.Asp194Asn and p.Ile144Leu amino acid substitutions, which exhibit discordant effects on PD. Furthermore, rare variant analysis of SCARB2 revealed mixed effect directions, with a balanced effect magnitude across the two directions. In such scenarios, the aggregate effect may appear null, despite the presence of biologically meaningful associations. The bidirectional effects have also been observed in genes like TMEM175 and CTSB, where opposing variant effects can obscure the cumulative genetic burden on disease risk. These findings underscore a key limitation of conventional burden analyses that rely on the assumption of effect directionality. On the other hand, understanding such discordance was crucial as it suggested that targeting a single specific pathogenic variant—rather than the gene as a whole—may be a more effective strategy in clinical interventions.

CTSB

We found CTSB rs1293298 as a significant risk factor only in the European and Complex Admixture History populations. Of note, CTSB rs1293298 in East Asians was excluded from the common variant analyses due to MAF <0.01. In the European cohort, we identified an independent common intronic variant (rs1293289), linked to the known GWAS hit CTSB rs1293298. In addition, CTSB rs73551266 was detected as a novel independent variant in the Latino and indigenous Americas population.

A recent study observed a nominal association between CTSB rare variants and PD risk in a European population³⁰. However, our large European cohort (24,208 cases, 9,662 controls) did not replicate this result. In contrast to the previous study, we excluded carriers of GBA1 variants from all cohorts to minimize potential bias, which may partly explain the discrepancy. Our findings further support the limitation of rare variant burden analysis, particularly in genes like TMEM175 and CTSB, where both risk and protective variants may co-exist. Besides, future studies should focus on larger sample size in other populations to increase robustness.

GBA1

We performed gene-based and single-variant-based tests in AMP-PD dataset to estimate genetic burden of rare variants in GBA1 gene. Our results replicate and validate the established association with GBA1. We detected a genetic burden of GBA1 rare variants on PD in the European population from the AMP-PD dataset, in concordance with results from previous work^7,31. GBA1 p. Asn409Ser was shown to be associated with PD risk on a single variant level. This specific mutation is classified as a “mild” mutation based on its phenotype in homozygous carriers with Gaucher disease^32,33.

The associations of known GWAS hits with PD in other populations were observed although not reaching genome wide significance. This discrepancy may reflect distinct LD patterns, differences in haplotype structures among populations or limited statistical power due to smaller cohort size. Future haplotype-resolved analyses (e.g., phased whole-genome sequencing or ancestry-stratified fine-mapping) could clarify whether these associations arise from shared causal variants present on divergent haplotypes or population-specific functional variants embedded within risk haplotypes. On the other hand, our study illustrates heterogeneity in genetic associations across populations in PD. These combined analyses emphasize these three lysosomal related genes (TMEM175, SCARB2 and CTSB) driving PD risk via both common variants and rare variants. Future research should prioritize detailed functional characterization of these novel variants and their potential patho-mechanism in diverse populations to uncover their roles, facilitating improved understanding and potential development of targeted interventions for PD.

The strength of this study is the analysis of a large-scale case-control cohort from the GP2 Neurobooster array with a population of European ancestry and 10 additional populations as well as WGS data from the AMP-PD dataset. There are some limitations. The observed replication may, in part, be influenced by partial sample overlap with the 2019 PD GWAS cohort. Notably, 7 out of the 126 cohorts included in our study were included in the previous Nalls’s PD GWAS. It is not possible to identify exactly which samples overlap, because the genotyping arrays are so different that kinship analysis does not identify related/duplicated samples. Despite this limitation, our study reinforces the association between lysosomal genes and PD risk in the European population. Additionally, the number of non-European individuals will need to be increased in future studies, being clearly smaller compared to the European cohort.

PD is a complex disorder with many genetic risk factors at multiple loci contributing to disease risk. Therefore, the novel variants reported in this study should be further investigated in terms of functional effects on PD pathogenesis in the future.